



Press Release

Friday, May 5, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road
Bangalore – 560076

Strides Shasun announces successful completion of third consecutive US FDA inspection with “Zero 483 Status” over the last month

Bangalore, May 5, 2017 - Strides Shasun today announced that its Active Pharmaceutical Ingredients (API) manufacturing site in Puducherry was recently inspected by US FDA and the approval was renewed with ‘Zero 483’ status.

Over the last month, three facilities were inspected by US FDA and cleared with Zero 483 Status.

- API facility at Cuddalore from 17th April 2017 to 21st April 2017;
- Oral Dosage facility at Puducherry from April 24th 2017 to April 28th 2017; and
- API facility at Puducherry from 1st May 2017 to 5th May 2017.

The Company’s flagship Facility (KRSG Gardens) in Bangalore was also inspected and cleared by US FDA in June 2016 with “Zero 483” observations.

With this, the Company’s last four US FDA inspections were successfully completed without any observations.

Commenting on the development, Shashank Sinha, Group CEO of Strides Shasun stated, “We are delighted with the outcome of the recent US FDA inspections at three of our main facilities. This is a strong endorsement of our significant investment and ongoing focus on compliance integrity. We remain committed to meet and exceed the expectation of the authorities in the challenging regulatory landscape as it continues to evolve”.

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 8 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 2 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

<p><u>Strides Shasun</u></p> <p>Shashank Sinha, Group CEO +91 80 6784 0335</p> <p>Vikesh Kumar +91 80 6784 0827 Kannan N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791</p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com</p> <p>K Priya: +91 9535425418 priya@fortunapr.com</p>
---	---